Free press releases distribution network?

Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



PERT Consortium and BTG Form Strategic Partnership - BTG plc announced a strategic partnership with the PERT Consortium™ to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT™ programs across the U.S - PERTConsortium.org / BTGplc.com
PERT Consortium and BTG Form Strategic Partnership

 

PRTODAY - Newswire & PRZOOM/ - Bothell, WA, United States, 06/21/2018 - BTG plc announced a strategic partnership with the PERT Consortium™ to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT™ programs across the U.S - PERTConsortium.org / BTGplc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG plc, the global healthcare company, today announced at the annual PERT Consortium™ Meeting in Nashville, TN, a strategic partnership with the PERT Consortium™ to advance the science of Pulmonary Embolism (PE) treatment and promote the implementation of PERT™ programs across the U.S.

In the United States, pulmonary embolism afflicts 500,000 600,000 patients annually1,2 and is either a primary or secondary cause of death in 150,000 200,000 of these individuals2. In their new partnership, BTG and the PERT Consortium™ are uniting to address this disease via expanding options for professional education, expanding clinical research, establishing quality benchmarks for care of PE, and developing new mobile technologies to convene PERT teams and improve decision-making.

“With this partnership, we are reaffirming our long-standing commitment to improving patient care and reducing in-hospital mortality associated with Pulmonary Embolism,” said BTG Chief Medical Officer, Francis Facchini. “By partnering with the PERT Consortium™, we hope to develop new strategies to transform the PE treatment paradigm.”

“We applaud BTG’s commitment to research and their leadership in the field of PE,” said PERT Consortium™ President, Victor Tapson. “This partnership will expand the body of clinical evidence and improve multi-disciplinary decision-making for PE patients.”

“PE is a pervasive disease that is under-recognized and undertreated,” according to Consortium Immediate Past-president Kenneth Rosenfield. “Our collaboration with BTG will enable the PERT Consortium™ to increase provider and patient awareness about PE, and establish new benchmarks for high quality care of the patient with this disease.”

About Pulmonary Embolism
Pulmonary Embolism (PE) is a condition that occurs when a piece of a blood clot breaks off from a clot in the legs and travels through the vasculature -- getting trapped in the Pulmonary Arteries. When this happens, the clot blocks blood from getting to some areas of the lungs to receive oxygen. This may lead to excessive strain on the right side of the heart, ultimately leading to heart failure and/or cardiovascular collapse. PEs can be immediately fatal, but if diagnosed and appropriate therapy started, mortality can be reduced from approximately 30 percent to less than 10 percent.

About Pulmonary Embolism Response Teams (PERT)
The first PERT™ was created by a multi-disciplinary team of physicians at Massachusetts General Hospital (MGH) in 2012. Their intent was to develop the necessary clinical, educational, and research infrastructure for the advancement of PE care. Since then, the PERT™ multidisciplinary approach has allowed for the streamlined evaluation of patients, formulation of comprehensive treatment plans and the rapid mobilization of resources to provide the highest level of care to those in need. The PERT™ model has since grown in popularity and continues to be adopted by institutions across the US and beyond.

About the PERT Consortium
The PERT Consortium™ (pertconsortium.org) is a not-for-profit 501c3 organization, whose mission is to serve the general public by undertaking activities to advance the status of PE care and promote research, enhance quality, and optimize outcome in the treatment of pulmonary embolism. Specifically, the Consortium intends to: 1) Promote the adoption of the PERT model in healthcare institutions across the United States to ensure the prompt diagnosis and high quality treatment of pulmonary embolism; 2) Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavors; 3) Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.

About BTG
BTG (btgplc.com) is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. BTG’s Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins.

Reference materials as the remarks in the press release:

1. The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. US Department of Health and Human Services report, 2008.
2. Ansari A. Acute and chronic pulmonary thromboembolism: current perspectives. I. Glossary of terms, historic evolution and prevalence. Clinical Cardiology(1986), 9:398-402

Contacts
Andy Burrows, VP Corporate & Investor Relations - BTG
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

Stuart Hunt, Investor Relations Manager - BTG
P: +44(0)20 7575 1582 / M: +44(0)78 1577 8536

Chris Gale, Vice President - Greentarget Communications
P: +1 646-695-2883 / M: +1 203-570-4681

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PERT Consortium and BTG Form Strategic Partnership

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
The PERT Consortium™ | BTG plc
Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)77 7325 1178 (mobile) chris.sampson[.]btgplc.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: PERT Consortium and BTG Form Strategic PartnershipAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

EC Approves Ipsen’s Cabometyx® (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
Neurent Medical's RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan
Market Entrants Offering Digitized Mass Spectrometry Solutions Gain a Competitive Edge over Traditional Vendors Finds Frost & Sullivan
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis
Medtech & Pharma Platform Annual Event Celebrates its 5th Anniversary in Basel
Ipsen to Present New Data from its Oncology Portfolio At The 2018 European Society for Medical Oncology (ESMO) Congress
Arla Foods Ingredients Acclaimed by Frost & Sullivan for its Osteopontin-enriched ingredient, Lacprodan® OPN-10
SCHOTT Teams Up with Smart Skin Technologies
STEMCELL Technologies Signs Exclusive License to Commercialize Human Pluripotent Stem Cell-Derived Kidney Organoid Culture System
Swedish Government and GE Healthcare Open an Innovation Center for Life Sciences

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  JobsWare.com

Visit  NAKIVO, Inc.

Visit  BizJobs.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)